Skip to search formSkip to main contentSkip to account menu

yoshi 864

Known as: Compound 864, Yoshi-864, alkylating agent 864 
An alkylsulfonate. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication. (NCI04)
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

improsanimprosan hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Macro-Econophysics : New Studies on Economic Networks and Synchronization
Review of: Macro-Econophysics: New Studies on Economic Networks and Synchronization. By Hideaki Aoyama, Yoshi Fujiwara, Yuichi… 
2002
2002
Impairment of synaptic vesicle exocytosis and recycling during neuromuscular weakness produced in mice by 2,4-dithiobiuret.
Chronic treatment of rodents with 2,4-dithiobiuret (DTB) induces a neuromuscular syndrome of flaccid muscle weakness that mimics… 
1983
1983
Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix.
1978
1978
Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors.
Two hundred and eight acceptable patients were treated with Yoshi 864 (2 mg/kg/day by iv push X 5 days repeated once every 6… 
1976
1976
Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864).
Asynchronous human lymphoma cells treated for 1 hour with increasing concentrations of 1-propanol, 3,3'-iminodi… 
1976
1976
Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
Six antitumor platinum compounds were used in combination with cyclophosphamide plut 1 of 7 other antitumor drugs for treatment… 
1975
1975
Systemic chemotherapy of advanced head and neck malignancies
Several Phase II chemotherapy protocols were evaluated in patients with advanced malignancies; 158 were evaluable head and neck… 
1975
1975
Yoshi 864 (NSC 102627) 1‐propanol, 3, 3′‐iminodi‐dimethanesulfonate (ester) hydrochloride: A phase I study
Yoshi 864 was given i.v. push daily × 5 with 6 weeks' followup. Dose escalation was from 0.25 mg/kg to 2.7 mg/kg. Toxicity and… 
1975
1975
Comparative Effects of Yoshi-864 and Busulfan on Certain Transplantable Murine Tumors 1
Summary Yoshi-864 extends markedly the survival times of mice bearing L1210 leukemia or Ehrlich ascites carcinoma. Busulfan, with… 
Review
1961
Review
1961
Dermatology: the eccrine sweat glands.
Although much is known about the human eccrine sweat glands as a re­ sult of extensive studies carried out during the past half… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)